Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Llombart-Cussac A, Prat A, Pérez-García JM, Mateos J, Pascual T, Escrivà-de-Romani S, Stradella A, Ruiz-Borrego M, de Las Heras BB, Keyaerts M, Galvan P, Brasó-Maristany F, García-Mosquera JJ, Guiot T, Gion M, Sampayo-Cordero M, Di Cosimo S, Pérez-Escuredo J, de Frutos MA, Cortés J, Gebhart G. Llombart-Cussac A, et al. Among authors: gion m. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2733-2743. doi: 10.1007/s00259-024-06683-0. Epub 2024 Apr 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587643 Free PMC article. Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: gion m. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Among authors: gion m. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. Nat Med. 2024. PMID: 39271844 Free PMC article. Clinical Trial.
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.
Bartsch R, Pérez-García JM, Furtner J, Berghoff AS, Marhold M, Starzer AM, Hughes M, Kabraji S, Sammons S, Anders C, Murthy RK, Van Swearingen AED, Pereslete A, Gion M, Vaz Batista M, Braga S, Pinto PBC, Sampayo-Cordero M, Llombart-Cussac A, Preusser M, Cortés J, Lin NU. Bartsch R, et al. Among authors: gion m. ESMO Open. 2025 Jan 3;10(1):104092. doi: 10.1016/j.esmoop.2024.104092. Online ahead of print. ESMO Open. 2025. PMID: 39754978 Free article.
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Among authors: gion m. Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0. Nat Med. 2024. PMID: 39653780 Free PMC article. No abstract available.
Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.
Cortés-Salgado A, Serrano JJ, Cordero Pereda D, Menacho M, Del Rey JM, Del Campo-Albendea L, Saavedra C, Chamorro J, Rosero D, Sotoca P, Guillén-Ponce C, Guerra E, Fernández-Abad M, López-Miranda E, Martínez-Jáñez N, Gion M, Salazar MT, Agudo-Quílez P, Garrido P, Alonso Salinas GL. Cortés-Salgado A, et al. Among authors: gion m. Oncologist. 2024 Nov 19:oyae299. doi: 10.1093/oncolo/oyae299. Online ahead of print. Oncologist. 2024. PMID: 39561108 Free article.
Moving toward response-adapted trials in oncology.
Pérez-García J, Antonarelli G, Gion M, Llombart-Cussac A, Cortés J. Pérez-García J, et al. Among authors: gion m. Nat Med. 2024 Dec;30(12):3426-3428. doi: 10.1038/s41591-024-03346-3. Nat Med. 2024. PMID: 39528666 No abstract available.
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis.
Ravaggi A, Bergamaschi C, Galbiati C, Zanotti L, Fabricio ASC, Gion M, Cappelletto E, Leon AE, Gennarelli M, Romagnolo C, Ciravolo G, Calza S, Bignotti E, Odicino F. Ravaggi A, et al. Among authors: gion m. Biomedicines. 2024 Oct 19;12(10):2393. doi: 10.3390/biomedicines12102393. Biomedicines. 2024. PMID: 39457705 Free PMC article.
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, De Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S. Hamilton E, et al. Among authors: gion m. Clin Cancer Res. 2024 Dec 16;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513. Clin Cancer Res. 2024. PMID: 39405343 Free PMC article. Clinical Trial.
255 results